Pasar al contenido principal

ENFERMEDADES METABOLICAS Y CANCER

RED2018-102799-T

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Redes Investigación /Redes Excelencia
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 20
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Apolipoprotein and lrp1‐based peptides as new therapeutic tools in atherosclerosis

  • Benitez-Amaro, Aleyda
  • Solanelles Curco, Angels
  • García, Eduardo
  • Julve, Josep
  • Rives, José
  • Benítez, Sonia
  • Llorente-Cortés, Vicenta
Apolipoprotein (Apo)‐based mimetic peptides have been shown to reduce atherosclerosis. Most of the ApoC‐II and ApoE mimetics exert anti‐atherosclerotic effects by improving lipid profile. ApoC‐II mimetics reverse hypertriglyceridemia and ApoE‐based peptides such as Ac‐hE18A‐NH2 reduce cholesterol and triglyceride (TG) levels in humans. Conversely, other classes of ApoE and ApoA‐I mimetic peptides and, more recently, ApoJ and LRP1‐based peptides, exhibit several antiatherosclerotic actions in experimental models without influencing lipoprotein profile. These other mimetic peptides display at least one atheroprotective mechanism such as providing LDL stability against mechanical modification or conferring protection against the action of lipolytic enzymes inducing LDL aggregation in the arterial intima. Other anti‐atherosclerotic effects exerted by these peptides also include protection against foam cell formation and inflammation, and induction of reverse cholesterol transport. Although the underlying mechanisms of action are still poorly described, the recent findings suggest that these mimetics could confer atheroprotection by favorably influencing lipoprotein function rather than lipoprotein levels. Despite the promising results obtained with peptide mimetics, the assessment of their stability, atheroprotective efficacy and tissue targeted delivery are issues currently under progress., The economic support was received from Fundació MARATÓ TV3 with the grant 201521- 10 (to V.L.C), FIS PI18/01584 (to V.L.C) and FIS PI19/00421 (to S.B.) from the Instituto de Salud Carlos III (ISCIII) and co-financed with ERDFs and from Ayudas Fundación BBVA a Equipos de Investigación Científica en Biomedicina 2019. A.B.A. is a predoctoral fellow (FI19/00205) granted by the Programme _Contratos predoctorales de formación de investigación en salud_and J.J. is recipient of a Miguel Servet Type 2 contract (CPII18/00004) from the Instituto de Salud Carlos III (ISCIII) and co-financed with ERDFs. E.G. Grant support was also received from Fundación BBVA (Project “Translational Molecular Imaging for Detection of Cholesterol Entrapment in the Vasculature with 68Ga-labeled LRP1-derived Peptides”). The team is part of CIBER Enfermedades Cardiovasculares (CIBERCV; CB16/11/00276 to V.L.C.) and CIBER Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM; CB07/08/0016 to J.J.), projects run by the Instituto de Salud Carlos III. The team also participates in Redes de investigación (Enfermedades Metabólomicas y Cáncer RED2018-102799-T), a project run by MINECO. A.B.A., E.G., J.J., S.B. and V.L.C. are members of the Vascular Biology Group of the Spanish Atherosclerosis Society.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Peptides against Low Density Lipoprotein (LDL) Aggregation Inhibit Intracellular Cholesteryl Ester Loading and Proliferation of Pancreatic Tumor Cells

  • Benitez-Amaro, Aleyda
  • Martínez-Bosch, Neus
  • Manero-Rupérez, Noemí
  • Claudi, Lene
  • La Chica Lhoëst, Maria Teresa
  • Soler, Marta
  • Ros-Blanco, Lia
  • Navarro Medrano, Pilar
  • Llorente-Cortés, Vicenta
Dyslipidemia, metabolic disorders and/or obesity are postulated as risk factors for pancreatic ductal adenocarcinoma (PDAC). The majority of patients with these metabolic alterations have low density lipoproteins (LDLs) with increased susceptibility to become aggregated in the extracellular matrix (ECM). LDL aggregation can be efficiently inhibited by low-density lipoprotein receptor-related protein 1 (LRP1)-based peptides. The objectives of this work were: (i) to determine if aggregated LDLs affect the intracellular cholesteryl ester (CE)/free cholesterol (FC) ratio and/or the tumor pancreatic cell proliferation, using sphingomyelinase-modified LDL particles (Aggregated LDL, AgLDL); and (ii) to test whether LRP1-based peptides, highly efficient against LDL aggregation, can interfere in these processes. For this, we exposed human pancreatic cancer cell lines (PANC-1, RWP-1 and Capan-1) to native (nLDL) or AgLDLs in the absence or presence of LRP1-based peptides (DP3) or irrelevant peptides (IP321). Results of thin-layer chromatography (TLC) following lipid extraction indicate that AgLDLs induce a higher intracellular CE/FC ratio than nLDL, and that DP3 but not IP321 counteracts this effect. AgLDLs also increase PANC-1 cell proliferation, which is inhibited by the DP3 peptide. Our results indicate that AgLDL-induced intracellular CE accumulation plays a crucial role in the proliferation of pancreatic tumor cell lines. Peptides with anti-LDL aggregation properties may thus exhibit anti-tumor effects., This research was funded by Fundación BBVA Convocatoria Ayudas a Equipos de Investigación Científica Fundación BBVA 2019, en el área de Biomedicina (to V.Ll-C), FIS PI18/01584 (to V.L.-C.), and FIS PI20/00625 (to P.N.) from the Instituto de Salud Carlos III (ISCIII) and co-financed with ERDFs. A.B.-A. is a predoctoral fellow (FI19/00205) granted by the Programme Predoctoral Contracts for Health Research Training from Instituto de Salud Carlos III (ISCIII) and co-financed with ERDFs. Our group is part of CIBER Enfermedades Cardiovasculares (CIBERCV; CB16/11/00276 V.Ll-C), a project run by the Instituto de Salud Carlos III. Our group also participates in Redes de investigación (Enfermedades Metabólicas y Cáncer RED2018-102799-T), a project run by MINECO. Our group has been recognized by Generalitat de Catalunya (2017 SGR 946 to V.L.-C., and SGR 225 to P.N.). V.L.-C. and A.B.-A. are members of the Group of Vascular Biology of the Spanish Society of Atherosclerosis (SEA).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis

  • Martínez-Bosch, Neus
  • Cristóbal, Helena
  • Iglesias, Mar
  • Gironella, Meritxell
  • Barranco, Luis E.
  • Visa, Laura
  • Calafato, Domenico
  • Jiménez-Parrado, Silvia
  • Earl, Julie
  • Carrato, Alfredo
  • Manero-Rupérez, Noemí
  • Moreno-Estellés, Mireia
  • Morales, Albert
  • Guerra, Carmen
  • Navarro Medrano, Pilar
  • García de Frutos, Pablo
Background: Early diagnosis is crucial for patients with pancreatic ductal adenocarcinoma (PDAC). The AXL receptor tyrosine kinase is proteolytically processed releasing a soluble form (sAXL) into the blood stream. Here we explore the use of sAXL as a biomarker for PDAC. Methods: AXL was analysed by immunohistochemistry in human pancreatic tissue samples. RNA expression analysis was performed using TCGA/GTEx databases. The plasma concentrations of sAXL, its ligand GAS6, and CA19-9 were studied in two independent cohorts, the HMar cohort (n = 59) and the HClinic cohort (n = 142), including healthy controls, chronic pancreatitis (CP) or PDAC patients, and in a familial PDAC cohort (n = 68). AXL expression and sAXL release were studied in PDAC cell lines and murine models. Findings: AXL is increased in PDAC and precursor lesions as compared to CP or controls. sAXL determined in plasma from two independent cohorts was significantly increased in the PDAC group as compared to healthy controls or CP patients. Patients with high levels of AXL have a lower overall survival. ROC analysis of the plasma levels of sAXL, GAS6, or CA19-9 in our cohorts revealed that sAXL outperformed CA19-9 for discriminating between CP and PDAC. Using both sAXL and CA19-9 increased the diagnostic value. These results were validated in murine models, showing increased sAXL specifically in animals developing PDAC but not those with precursor lesions or acinar tumours., This work was supported by grants from the Spanish Ministry of Science and Innovation (MICINN)/ Instituto de Salud Carlos III (ISCIII)-European Regional Development Fund (ERDF) (PI20/00625) and the “Generalitat de Catalunya” (2017/SGR/225) to PN; grants from the MICINN (Project# RTI2018-095672-BI00) to AM and PGdF; grant from the MICINN/ ISCIII-FEDER (PI20/01696) to MG and grant from the MICINN/ ISCIII-FEDER (PI18/01034) to AC. We also acknowledge grants from the Instituto de Salud Carlos III (ISCIII)/ERDF(PT20/00023) and the "Xarxa de Bancs de tumours” sponsored by Pla Director d'Oncologia de Catalunya (XBTC). PN’s lab is part of Redes de investigacion (Enfermedades Metabolicas y Cancer RED2018-102799-T), a project run by MINECO. CIBEREHD is funded by Instituto de Salud Carlos III.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Increased sLRP1 and decreased atrial natriuretic peptide plasma levels in newly diagnosed T2DM patients are normalized after optimization of glycemic control

  • García, Eduardo
  • Gil, Pedro
  • Miñambres, Inka
  • Benitez-Amaro, Aleyda
  • Rodríguez, Claudia
  • Claudi, Lene
  • Julve, Josep
  • Benitez, Sonia
  • Sánchez-Quesada, José Luís
  • Rives, Jose
  • Garcia-Moll, Xavier
  • Vilades, David
  • Moreno-Pérez, Antonio J.
  • Llorente-Cortés, Vicenta
Low-density lipoprotein receptor-related protein 1 (LRP1) negatively modulates circulating atrial natriuretic peptide (ANP) levels. Both molecules are involved in the regulation of cardiometabolism., The economic support to develop this project was received from: Fundació MARATÓ TV3with the grant 201521-10 (toVLl-C). Instituto de Salud Carlos III (ISCIII) and co-financed with ERDFs with the grantsPI16-00471 (to JS-Q), PI17-00232 (to JJ), PI20-00334 (to JLS-Q), FIS PI18/01584 and FIS PI21/01523 (to VLl-C). Fundación BBVA Ayudas a equipos de investigación 2019 (“Translational Molecular Imaging for Detection of Cholesterol Entrapment in the Vasculature with 68Ga-labeled LRP1-derived Peptides”) (to VLl-C). AB-A is a predoctoral fellow (FI19/00205) granted by the Programme_Contratos predoctorales de formaciónde investigaciónen salud_ fromthe Instituto de Salud Carlos III (ISCIII) and co-financed with ERDFs. The team is part of CIBER Enfermedades Cardiovasculares (CIBERCV; CB16/11/ 00276 to DV, XG-M and VLl-C), and CIBER Diabetes y Enfermedades MetabólicasAsociadas (CIBERDEM;CB07/08/0016 to JJ, JS-Q, andAP) run by the Instituto de Salud Carlos III. VLl-C and JJ are members of Redes de investigación (Enfermedades Metabólicas y Cáncer RED2018- 102799-T), a project run by MINECO. VLl-C, AB-A and DV are members of the Quality Research Group from Generalitat de Catalunya 2017 SGR 946 and JJ, SB and JS-Q of the 2017-SGR- 1149group. VLl-C, EG, AB-A, SB and JS-Q are members of the Spanish Atherosclerosis Society Vascular Biology Group. IRSANTPAUis a centre ofCERCAProgramme/Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mechanisms modulating foam cell formation in the arterial intima: exploring new therapeutic opportunities in atherosclerosis

  • La Chica Lhoëst, Maria Teresa
  • Martínez, Andrea
  • Claudi, Lene
  • García, E.
  • Benitez-Amaro, Aleyda
  • Polishchuk, Anna
  • Piñero, J.
  • Vilades, David
  • Guerra Ramos, José María
  • Sanz, F.
  • Rotllan, Noemi
  • Escolà-Gil, Joan Carles
  • Llorente-Cortés, Vicenta
In recent years, the role of macrophages as the primary cell type contributing to foam cell formation and atheroma plaque development has been widely acknowledged. However, it has been long recognized that diffuse intimal thickening (DIM), which precedes the formation of early fatty streaks in humans, primarily consists of lipid-loaded smooth muscle cells (SMCs) and their secreted proteoglycans. Recent studies have further supported the notion that SMCs constitute the majority of foam cells in advanced atherosclerotic plaques. Given that SMCs are a major component of the vascular wall, they serve as a significant source of microvesicles and exosomes, which have the potential to regulate the physiology of other vascular cells. Notably, more than half of the foam cells present in atherosclerotic lesions are of SMC origin. In this review, we describe several mechanisms underlying the formation of intimal foam-like cells in atherosclerotic plaques. Based on these mechanisms, we discuss novel therapeutic approaches that have been developed to regulate the generation of intimal foam-like cells. These innovative strategies hold promise for improving the management of atherosclerosis in the near future., The economic support to develop this project was received from FIS PI21/01523 (to VLl-C) from the Instituto de Salud Carlos III (ISCIII) and co-financed with ERDFs, and Fundación BBVA Ayudas a equipos de investigación 2019. Aleyda Benitez Amaro (ABA) is a postdoctoral fellow (FI19/00205) that was granted by the Programme Contratos predoctorales de formación de investigación en salud_from the Instituto de Salud Carlos III (ISCIII) and co-financed with ERDFs. The RIFS methodology required to analyze mitochondrial respiration in frozen cardiac samples was developed thanks to the AYUDAS PARA LA MOVILIDAD DE PERSONAL INVESTIGADOR CONTRATADO EN EL MARCO DE LA AES (M-AES) del ISCIII granted by ABA (MV21/00060). Our group is part of CIBER Enfermedades Cardiovasculares (CIBERCV; CB16/11/00276 to VLl-C), and CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM; CB07/08/016 to JC-EG and NR), projects run by the Instituto de Salud Carlos III. Our group also participates in Redes de investigación (Enfermedades Metabóloicas y Cáncer RED2018-102799-T), a project run by MINECO. We belong to a group recognized by Generalitat de Catalunya (2021 SGR 00834). This work was also funded by Ministerio de Ciencia, Innovación y Universidades (PID2022-137186OB-100), as well as from the Agencia Estatal de Investigación (AEI/10.13039/501100011033) within the Subprograma Ramón y Cajal (RYC-201722879) to NR. The IR SANT PAU is a centre of CERCA Programme/Generalitat de Catalunya, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Reduced blood EPAC1 protein levels as a marker of severe coronary artery disease: the role of hypoxic foam cell-transformed smooth muscle cells

  • García, Eduardo
  • Claudi, Lene
  • La Chica Lhoëst, Maria Teresa
  • Polishchuk, Anna
  • Samouillan, Valerie
  • Benitez-Amaro, Aleyda
  • Pinero, Janet
  • Escolà-Gil, Joan Carles
  • Sabidó, Eduard
  • Leta, Ruben
  • Vilades, David
  • Llorente-Cortés, Vicenta
Vascular smooth muscle cells loaded with cholesterol (foam-VSMCs) play a crucial role in the progression of human atherosclerosis. Exchange Protein Directly Activated by cAMP 1 (EPAC1) is a critical protein in the regulation of vascular tone, endothelial function, and inflammation. Our objectives were to identify proteins specifically secreted by foam human coronary VSMCs (foam-hcVSMC) to evaluate their potential as circulating biomarkers for diagnosing coronary artery disease (CAD), and to ascertain the mechanisms underlying their levels in the blood of patients with CAD., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. The development of this project was financially supported by FIS PI21/01523 and FIS PI24/00618 (to VLl-C) from the Instituto de Salud Carlos III (ISCIII) and co-financed by ERDFs. Eduardo Garcia (FPU21/01173) and Maria Teresa LaChica (FPU22/01888) are predoctoral fellows funded by the Spanish Ministry of Science, Innovation, and Universities in Spain. Aleyda Benitez Amaro (ABA) is a postdoctoral fellow funded by Programme Contratos Predoctorales de Formación en Investigación en Salud (FI19/00205) from ISCIII and co-financed by ERDFs. Anna Polischuk is a postdoctoral researcher funded by the collaborative program CSIC-UCRANIA (UCRAN20011). Our team is part of CIBER Enfermedades Cardiovasculares (CIBERCV; CB16/11/00276 to VLl-C and DV) and CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM, CB07/08/0016 to JCE-G), projects run by the Instituto de Salud Carlos III. Additionally, our group participates in the Redes de Investigación (Enfermedades Metabólicas y Cáncer RED2018-102799-T), a project funded by MINECO. We are also recognized by Generalitat de Catalunya (2021 SGR 00834). The IR-SANTPAU is a center of the CERCA Programme/Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Impaired cholesterol and LDL uptake pathways in the development of oncological and cardiovascular diseases

  • Solanelles Curco, Angels
  • García, Eduardo
  • Polishchuk, Anna
  • La Chica Lhoëst, Maria Teresa
  • Llorente-Cortés, Vicenta
Dietary lipids play a critical role in the development of cardiovascular disease and cancer by influencing key cellular processes. Lipoprotein and fatty acid receptors activate intracellular signaling pathways that promote tumor growth and vascular remodeling. A key event in both cancer and vascular diseases is the retention of low-density lipoproteins (LDL) and other lipoprotein particles by proteoglycans in the extracellular matrix (ECM) of atherosclerotic plaques and the tumor stroma. This retention facilitates lipoprotein modification processes. Dysregulated uptake of modified lipoproteins-particularly through receptors that are not downregulated by intracellular cholesterol levels-leads to excessive lipid accumulation within lipid droplets (LDs) and other intracellular organelles. The lipid and protein content of LDs and mitochondria determine the biophysical and functional characteristics of the crucial interactions between these suborgalles. In particular, lipid-derived mediators such as prostaglandins, leukotrienes, ceramides, oxidized fatty acids, and cholesterol can disrupt LD biogenesis and dynamics, impair mitochondrial function, and alter the expression, activity, and subcellular localization of proteins that regulate LD-mitochondria interactions. Dysfunctional communication between LDs and mitochondria contributes to the onset and progression of cancer and cardiovascular disease by disturbing cellular metabolism and energy homeostasis. Common LDL-related mechanisms in atherosclerosis and cancer have been summarized in Figure 1., The development of this project was financially supported by FIS PI21/01523 and FIS PI24/00618 (to VLl-C) from the Instituto de Salud Carlos III (ISCIII) and co-financed by ERDFs. Eduardo Garcia (FPU21/01173) and Maria Teresa LaChica (FPU22/01888) are predoctoral fellows funded by the Spanish Ministry of Science, Innovation, and Universities in Spain. Anna Polischuk is a postdoctoral researcher funded by the Collaborative Program CSIC-UCRANIA (UCRAN20011). Our team is part of CIBER Enfermedades Cardiovasculares (CIBERCV; CB16/11/00276 to VLl-C), a project run by the Instituto de Salud Carlos III. Additionally, our group participates in the Redes de Investigación (Enfermedades Metabólicas y Cáncer RED2018-102799-T), a project funded by MINECO. We are also recognized by Generalitat de Catalunya (2021 SGR 00834). The IR-SANTPAU is a center of the CERCA Programme/Generalitat de Catalunya. We acknowledge support from the Scientific Network Enfermedades Metabólicas funded by the Consejo Superior de Investigaciones Científicas (CSIC), Spain., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting LDL aggregation decreases atherosclerotic lipid burden in a humanized mouse model of familial hypercholesterolemia: Crucial role of ApoB100 conformational stabilization

  • Benitez-Amaro, Aleyda
  • García, Eduardo
  • La Chica Lhoëst, Maria Teresa
  • Martínez, A.
  • Borràs, Carla
  • Tondo, Mireia
  • Cespédes, Virtudes M.
  • Caruana, P.
  • Pepe, A.
  • Bochicchio, B.
  • Cenarro, Ana
  • Civeira, Fernando
  • Prades, Roger
  • Escolà-Gil, Joan Carles
  • Llorente-Cortés, Vicenta
Low-density lipoprotein (LDL) aggregation is nowadays considered a therapeutic target in atherosclerosis. DP3, the retro-enantio version of the sequence Gly1127-Cys1140 of LRP1, efficiently inhibits LDL aggregation and foam cell in vitro formation. Here, we investigate whether DP3 modulates atherosclerosis in a humanized ApoB100, LDL receptor (LDLR) knockout mice (Ldlr-/-hApoB100 Tg) and determine the potential LDL-related underlying mechanisms., The economic support to develop this project was received from FIS PI21/01523 (to VLl-C) and PI20/00623 (to MVC) from the Instituto de Salud Carlos III (ISCIII) and co-financed with ERDFs, and Fundación BBVA Ayudas a equipos de investigación 2019, and grants 2021SGR-Cat 00976 from AGAUR, Generalitat de Catalunya) (to MVC). ABA is a postdoctoral fellow (FI19/00205) that was granted by the Programme _Contratos predoctorales de formación de investigación en salud_from the Instituto de Salud Carlos III (ISCIII) and co-financed with ERDFs. M.V·C. was granted by a Miguel Servet contract (MSII/00007) from the Instituto de Salud Carlos III (ISCIII) and PC (FI21/00146) is a predoctoral fellow supported by the Programme_Contratos predoctorales de formación de investigación en salud_from ISCIII and co-financed with ERDFs. EG and MTLC-L were granted by the Ministry of Science, Innovation and Universities of Spain through the FPU predoctoral grants FPU21/01173 and FPU22/01888, respectively. Our group is part of CIBER Enfermedades Cardiovasculares (CIBERCV; CB16/11/00276 to VLl-C) and CIBER Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM; CB07/08/0016 to JCE-G), projects run by the Instituto de Salud Carlos III. Our group also participates in Redes de investigación (Enfermedades Metabóloicas y Cáncer RED2018-102799-T), a project run by MINECO. We belong to a group recognized by Generalitat de Catalunya (2021 SGR 00834). IR-SANTPAU is a centre of CERCA Programme/Generalitat de Catalunya., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

ApoB100 remodeling and stiffened cholesteryl ester core raise LDL aggregation in familial hypercholesterolemia patients

  • La Chica Lhoëst, Maria Teresa
  • Martínez, Andrea
  • Garcia, Eduardo
  • Dandurand, Jany
  • Polishchuk, Anna
  • Benitez-Amaro, Aleyda
  • Cenarro, Ana
  • Civeira, Fernando
  • Bernabé, Amable
  • Vilades, David
  • Escolà-Gil, Joan Carles
  • Samouillan, Valerie
  • Llorente-Cortes, Vicenta
Patients with familial hypercholesterolemia (FH) exhibit a significant residual cardiovascular risk. A new cardiovascular risk factor is the susceptibility of individual LDL particles to aggregation. This study examined LDL aggregation and its relationship with LDL lipid composition and biophysical properties in patients with FH compared to controls. LDL aggregation was measured as the change in particle size, assessed by dynamic light scattering, after exposure to sphingomyelinase, which breaks down sphingomyelin in the LDL phospholipid layer. Dynamic light scattering and transmission electron microscopy showed that LDL in FH patients exhibited smaller size and greater susceptibility to aggregation. Biochemical analyses revealed a higher cholesteryl ester (CE)/ApoB100 ratio in LDL from FH patients. Differential scanning calorimetry showed that LDL from FH patients had higher transition temperatures, indicating a more ordered CE core. Fourier transform infrared spectroscopy revealed fewer flexible α-helices (1658 cm⁻1) and more stable α-helices (1651 cm⁻1) in ApoB100 of LDL from FH patients. These structural changes correlated with higher CE content and increased LDL aggregation. In conclusion, a more ordered CE core in smaller LDL particles, combined with a higher proportion of stable α-helices in ApoB100, promotes LDL aggregation in FH patients. These findings suggest ApoB100 conformational structure as a new potential therapeutic targets within LDL to reduce cardiovascular risk in FH patients.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Targeting LDL aggregation decreases atherosclerotic lipid burden in a humanized mouse model of familial hypercholesterolemia: Crucial role of ApoB100 conformational stabilization

  • Benitez-Amaro, A.
  • Garcia, E.
  • La Chica Lhoëst, M.T.
  • Martínez, A.
  • Borràs, C.
  • Tondo, M.
  • Céspedes, M.V.
  • Caruana, P.
  • Pepe, A.
  • Bochicchio, B.
  • Cenarro, A.
  • Civeira, F.
  • Prades, R.
  • Escola-Gil, J.C.
  • Llorente-Cortés, V.
Background and aims: Low-density lipoprotein (LDL) aggregation is nowadays considered a therapeutic target in atherosclerosis. DP3, the retro-enantio version of the sequence Gly1127-Cys1140 of LRP1, efficiently inhibits LDL aggregation and foam cell in vitro formation. Here, we investigate whether DP3 modulates atherosclerosis in a humanized ApoB100, LDL receptor (LDLR) knockout mice (Ldlr / hApoB100 Tg) and determine the potential LDL-related underlying mechanisms. Methods: Tg mice were fed an HFD for 21 days to induce atherosclerosis and then randomized into three groups that received a daily subcutaneous administration (10 mg/kg) of i) vehicle, ii) DP3 peptide, or iii) a non-active peptide (IP321). The in vivo biodistribution of a fluorescent-labeled peptide version (TAMRA-DP3), and its colocalization with ApoB100 in the arterial intima, was analyzed by imaging system (IVIS) and confocal mi-croscopy. Heart aortic roots were used for atherosclerosis detection and quantification. LDL functionality was analyzed by biochemical, biophysical, molecular, and cellular studies. Results: Intimal neutral lipid accumulation in the aortic root was reduced in the DP3-treated group as compared to control groups. ApoB100 in LDLs from the DP3 group exhibited an increased percentage of α-helix secondary structures and decreased immunoreactivity to anti-ApoB100 antibodies. LDL from DP3-treated mice were pro-tected against passive and sphingomyelinase (SMase)-induced aggregation, although they still experienced SMase-induced sphingomyelin phospholysis. In patients with familial hypercholesterolemia (FH), DP3 efficiently inhibited both SMase-induced phospholysis and aggregation. Conclusions: DP3 peptide administration inhibits atherosclerosis by preserving the α-helix secondary structures of ApoB100 in a humanized ApoB100 murine model that mimicks the hallmark of human hypercholesterolemia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis

  • Martínez Bosch, Neus|||0000-0003-3596-0039
  • Cristóbal, Helena
  • Iglesias, Mar|||0000-0002-2274-4671
  • Gironella, Meritxell|||0000-0003-4437-5181
  • Barranco, Luis E
  • Visa, Laura|||0000-0002-3409-8857
  • Calafato, Domenico|||0000-0002-9636-9819
  • Jiménez-Parrado, Silvia
  • Earl, Julie
  • Carrato, Alfredo|||0000-0001-7749-8140
  • Manero-Rupérez, Noemí
  • Moreno Merino, Mireia|||0000-0001-9575-5112
  • Morales, Albert|||0000-0001-8702-2269
  • Guerra, Carmen
  • Navarro, Pilar|||0000-0003-4314-4584
  • García de Frutos, Pablo|||0000-0003-1547-1190
Early diagnosis is crucial for patients with pancreatic ductal adenocarcinoma (PDAC). The AXL receptor tyrosine kinase is proteolytically processed releasing a soluble form (sAXL) into the blood stream. Here we explore the use of sAXL as a biomarker for PDAC. AXL was analysed by immunohistochemistry in human pancreatic tissue samples. RNA expression analysis was performed using TCGA/GTEx databases. The plasma concentrations of sAXL, its ligand GAS6, and CA19-9 were studied in two independent cohorts, the HMar cohort (n = 59) and the HClinic cohort (n = 142), including healthy controls, chronic pancreatitis (CP) or PDAC patients, and in a familial PDAC cohort (n = 68). AXL expression and sAXL release were studied in PDAC cell lines and murine models. AXL is increased in PDAC and precursor lesions as compared to CP or controls. sAXL determined in plasma from two independent cohorts was significantly increased in the PDAC group as compared to healthy controls or CP patients. Patients with high levels of AXL have a lower overall survival. ROC analysis of the plasma levels of sAXL, GAS6, or CA19-9 in our cohorts revealed that sAXL outperformed CA19-9 for discriminating between CP and PDAC. Using both sAXL and CA19-9 increased the diagnostic value. These results were validated in murine models, showing increased sAXL specifically in animals developing PDAC but not those with precursor lesions or acinar tumours. sAXL appears as a biomarker for early detection of PDAC and PDAC-CP discrimination that could accelerate treatment and improve its dismal prognosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Particle size and cholesterol content of circulating HDL correlate with cardiovascular death in chronic heart failure

  • Teis, Albert|||0000-0002-4820-0736
  • Cediel, Germán|||0000-0001-9667-7507
  • Amigó, Núria|||0000-0002-0116-9145
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Aranyó, Júlia
  • Andrés-Cordón, Joan Francesc|||0000-0003-4264-4499
  • Puig Jové, Carlos|||0000-0001-9466-2627
  • Castelblanco, Esmeralda|||0000-0002-2061-6270
  • Gual-Capllonch, Francisco
  • Ferrer-Sistach, Elena|||0000-0002-1795-2193
  • Vallejo Camazón, Núria|||0000-0001-6644-6767
  • Juncà Puig, Gladys|||0000-0002-4421-5658
  • López Ayerbe, Jorge|||0009-0008-8495-0877
  • de Antonio Ferrer, Marta|||0000-0002-4319-797X
  • Domingo, Mar|||0000-0002-2935-1272
  • Santiago Vacas, Evelyn|||0000-0001-7511-406X
  • Codina, Pau|||0000-0002-2469-5711
  • Mauricio, Didac|||0000-0002-2868-0250
  • Lupón, Josep|||0000-0002-5601-9611
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Evidence regarding any association of HDL-particle (HDL-P) derangements and HDL-cholesterol content with cardiovascular (CV) death in chronic heart failure (HF) is lacking. To investigate the prognostic value of HDL-P size (HDL-Sz) and the number of cholesterol molecules per HDL-P for CV death in HF patients. Outpatient chronic HF patients were enrolled. Baseline HDL-P number, subfractions and HDL-Sz were measured using 1H-NMR spectroscopy. The HDL-C/P ratio was calculated as HDL-cholesterol over HDL-P. Endpoint was CV death, with non-CV death as the competing event. 422 patients were included and followed-up during a median of 4.1 (0-8) years. CV death occurred in 120 (30.5%) patients. Mean HDL-Sz was higher in CV dead as compared with survivors (8.39 nm vs. 8.31 nm, p < 0.001). This change in size was due to a reduction in the percentage of small HDL-P (54.6% vs. 60% for CV-death vs. alive; p < 0.001). HDL-C/P ratio was higher in the CV-death group (51.0 vs. 48.3, p < 0.001). HDL-Sz and HDL-C/P ratio were significantly associated with CV death after multivariable regression analysis (HR 1.22 [95% CI 1.01-1.47], p = 0.041 and HR 1.04 [95% CI 1.01-1.07], p = 0.008 respectively). HDL-Sz and HDL-C/P ratio are independent predictors of CV death in chronic HF patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases

  • Diarte-Añazco, E. M. G.|||0000-0003-3876-9918
  • Méndez Lara, Karen Alejandra|||0000-0002-8372-2310
  • Pérez, Antonio|||0000-0001-5528-1143
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Julve i Gil, Josep|||0000-0002-6531-2246
Sphingolipids are key signaling molecules involved in the regulation of cell physiology. These species are found in tissues and in circulation. Although they only constitute a small fraction in lipid composition of circulating lipoproteins, their concentration in plasma and distribution among plasma lipoproteins appears distorted under adverse cardiometabolic conditions such as diabetes mellitus. Sphingosine-1-phosphate (S1P), one of their main representatives, is involved in regulating cardiomyocyte homeostasis in different models of experimental cardiomyopathy. Cardiomyopathy is a common complication of diabetes mellitus and represents a main risk factor for heart failure. Notably, plasma concentration of S1P, particularly high-density lipoprotein (HDL)-bound S1P, may be decreased in patients with diabetes mellitus, and hence, inversely related to cardiac alterations. Despite this, little attention has been given to the circulating levels of either total S1P or HDL-bound S1P as potential biomarkers of diabetic cardiomyopathy. Thus, this review will focus on the potential role of HDL-bound S1P as a circulating biomarker in the diagnosis of main cardiometabolic complications frequently associated with systemic metabolic syndromes with impaired insulin signaling. Given the bioactive nature of these molecules, we also evaluated its potential of HDL-bound S1P-raising strategies for the treatment of cardiometabolic disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

NAD+-Increasing Strategies to Improve Cardiometabolic Health?

  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Canyelles, Marina|||0000-0002-0278-5337
  • Mauricio, Didac|||0000-0002-2868-0250
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Julve i Gil, Josep|||0000-0002-6531-2246
Depleted nicotinamide adenine dinucleotide (NAD+) is a common hallmark of metabolic disorders. Therefore, NAD+-increasing strategies have evolved as a potential therapeutic venue to combat cardiometabolic diseases. Several forms of vitamin B3, i.e., nicotinamide and nicotinamide mononucleotide, and especially nicotinamide riboside, have attracted most interest as potentially safe and efficacious candidates for NAD+ restoration. Herein, we dissected the characteristics of the latest clinical trials testing the therapeutic potential of different vitamin B3 molecules to improve cardiometabolic health, with a special focus on randomized, placebo-controlled clinical trials performed in the context of obesity or other pathologies, mainly linked to cardiovascular system and skeletal muscle functionality. The favorable outcomes via NAD+-increasing strategies found in the different studies were quite heterogeneous. NAD+-increasing interventions improved capacity to exercise, decreased blood pressure, increased the anti-inflammatory profile and insulin-stimulated glucose disposal, and reduced the fat-free mass. Except for the decreased blood pressure, the significant results did not include many hard clinical end points, such as decreases in weight, BMI, fasting glucose, or HbA1c percentage. However, the analyzed trials were short-term interventions. Overall, the accumulated clinical data can be interpreted as moderately promising. Additional and long-term studies will be needed to directly compare the doses and duration of treatments among different vitamin B3 regimes, as well as to define the type of patients, if any, that could benefit from these treatments. In this context, a major point of advancement in delineating future clinical trials would be to identify subjects with a recognized NAD+ deficiency using novel, appropriate biomarkers. Also, confirmation of gender-specific effect of NAD+-increasing treatments would be needed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

TMAO and Gut Microbial-Derived Metabolites TML and γBB Are Not Associated with Thrombotic Risk in Patients with Venous Thromboembolism

  • Canyelles, Marina|||0000-0002-0278-5337
  • Plaza, Melania|||0000-0002-1471-3672
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Llobet, Dolors
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Mojal, Sergi|||0000-0003-0523-3869
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
  • Soria Fernández, José Manuel|||0000-0002-6226-4293
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Souto, Juan Carlos|||0000-0003-2092-5142
Background: The present work evaluates the association between circulating concentrations of Trimethylamine-N-oxide (TMAO), gamma butyrobetaine (γBB), and trimetyllisine (TML) in controls and patients with venous thromboembolism (VTE) with coagulation parameters. Methods: The study involved 54 VTE patients and 57 controls. Platelet function, platelet hyperreactivity, platelet adhesiveness, thrombosis-associated parameters, and thrombin generation parameters were studied. Plasma TMAO, γBB, and TML determination was performed using an ultra-high-performance liquid chromatography system coupled with mass spectrometry. Results: No differences were found for TMAO, γBB, or TML concentrations between controls and VTE patients. In thrombin generation tests, TMAO, γBB, and TML showed a positive correlation with lag time and time to peak. TMAO, γBB, and TML negatively correlated with peak height. No significant differences were observed regarding TMAO, γBB, and TML concentrations between the two blood withdrawals, nor when the control and VTE patients were analyzed separately. No correlation was observed between these gut metabolites and platelet function parameters. Conclusions: No differences were found regarding TMAO, γBB, and TML concentrations between the control and VTE groups. Some correlations were found; however, they were mild or went in the opposite direction of what would be expected if TMAO and its derivatives were related to VTE risk.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Apolipoprotein and lrp1-based peptides as new therapeutic tools in atherosclerosis

  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Solanelles Curco, Angels
  • García Rodríguez, Jesús Eduardo|||0000-0002-7758-6789
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Benitez, Sonia|||0000-0003-3565-0743
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Apolipoprotein (Apo)-based mimetic peptides have been shown to reduce atherosclerosis. Most of the ApoC-II and ApoE mimetics exert anti-atherosclerotic effects by improving lipid profile. ApoC-II mimetics reverse hypertriglyceridemia and ApoE-based peptides such as Ac-hE18A-NH2 reduce cholesterol and triglyceride (TG) levels in humans. Conversely, other classes of ApoE and ApoA-I mimetic peptides and, more recently, ApoJ and LRP1-based peptides, exhibit several antiatherosclerotic actions in experimental models without influencing lipoprotein profile. These other mimetic peptides display at least one atheroprotective mechanism such as providing LDL stability against mechanical modification or conferring protection against the action of lipolytic enzymes inducing LDL aggregation in the arterial intima. Other anti-atherosclerotic effects exerted by these peptides also include protection against foam cell formation and inflammation, and induction of reverse cholesterol transport. Although the underlying mechanisms of action are still poorly described, the recent findings suggest that these mimetics could confer atheroprotection by favorably influencing lipoprotein function rather than lipoprotein levels. Despite the promising results obtained with peptide mimetics, the assessment of their stability, atheroprotective efficacy and tissue targeted delivery are issues currently under progress.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Divergent Effects of Glycemic Control and Bariatric Surgery on Circulating Concentrations of TMAO in Newly Diagnosed T2D Patients and Morbidly Obese

  • Canyelles, Marina|||0000-0002-0278-5337
  • Pérez, Antonio|||0000-0001-5528-1143
  • Junza, Alexandra
  • Miñambres, Inka|||0000-0002-0899-3938
  • Yanes, Oscar|||0000-0003-3695-7157
  • Sardà, Helena|||0000-0002-0138-8217
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
High circulating concentrations of the gut microbiota-derived metabolite trimethylamine N-oxide (TMAO) are significantly associated with the risk of obesity and type 2 diabetes (T2D). We aimed at evaluating the impact of glycemic control and bariatric surgery on circulating concentrations of TMAO and its microbiota-dependent intermediate, γ-butyrobetaine (γBB), in newly diagnosed T2D patients and morbidly obese subjects following a within-subject design. Based on HbA1c concentrations, T2D patients achieved glycemic control. However, the plasma TMAO and γBB concentrations were significantly increased, without changes in estimated glomerular filtration rate. Bariatric surgery was very effective in reducing weight in obese subjects. Nevertheless, the surgery reduced plasma γBB concentrations without affecting TMAO concentrations and the estimated glomerular filtration rate. Considering these results, an additional experiment was carried out in male C57BL/6J mice fed a Western-type diet for twelve weeks. Neither diet-induced obesity nor insulin resistance were associated with circulating TMAO and γBB concentrations in these genetically defined mice strains. Our findings do not support that glycemic control or bariatric surgery improve the circulating concentrations of TMAO in newly diagnosed T2D and morbidly obese patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Reverse Cholesterol Transport Dysfunction Is a Feature of Familial Hypercholesterolemia

  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
Purpose of Review: We seek to establish whether high-density lipoprotein HDL metabolism and reverse cholesterol transport (RCT) impairment is an intrinsic feature of familial hypercholesterolemia (FH). Recent Findings: RCT from macrophages (m-RCT), a vascular cell type of major influence on atherosclerosis, is impaired in FH due to defective low-density lipoprotein receptor (LDLR) function via both the HDL- and LDL-mediated pathways. Potential mechanisms include impaired HDL metabolism, which is linked to increased LDL levels, as well as the increased transport of cellular unesterified cholesterol to LDL, which presents a defective catabolism. Summary: RCT dysfunction is consistently associated with mutation-positive FH linked to decreased HDL levels as well as impaired HDL remodeling and LDLR function. It remains to be explored whether these alterations are also present in less well-characterized forms of FH, such as cases with no identified mutations, and whether they are fully corrected by current standard treatments.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Mechanisms modulating foam cell formation in the arterial intima, exploring new therapeutic opportunities in atherosclerosis

  • La Chica Lhoëst, María Teresa|||0000-0002-9070-5973
  • Martinez, A.
  • Claudi, Lene
  • Garcia, E.
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Polishchuk, A.
  • Piñero, Janet|||0000-0003-1244-7654
  • Viladés Medel, David|||0000-0002-3638-9703
  • Guerra Ramos, José María|||0000-0001-5397-9177
  • Sanz, F.
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
In recent years, the role of macrophages as the primary cell type contributing to foam cell formation and atheroma plaque development has been widely acknowledged. However, it has been long recognized that diffuse intimal thickening (DIM), which precedes the formation of early fatty streaks in humans, primarily consists of lipid-loaded smooth muscle cells (SMCs) and their secreted proteoglycans. Recent studies have further supported the notion that SMCs constitute the majority of foam cells in advanced atherosclerotic plaques. Given that SMCs are a major component of the vascular wall, they serve as a significant source of microvesicles and exosomes, which have the potential to regulate the physiology of other vascular cells. Notably, more than half of the foam cells present in atherosclerotic lesions are of SMC origin. In this review, we describe several mechanisms underlying the formation of intimal foam-like cells in atherosclerotic plaques. Based on these mechanisms, we discuss novel therapeutic approaches that have been developed to regulate the generation of intimal foam-like cells. These innovative strategies hold promise for improving the management of atherosclerosis in the near future.